S046 Cutaneous Lupus and Dermatomyositis: Management Pearls and Pitfall for the General Dermatologist
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
A case-based approach will be utilized to describe practical clinical scenarios that will enable the resident or general dermatologist to appropriately diagnose and manage patients with cutaneous lupus erythematosus and dermatomyositis. The importance of a thorough and intentional clinical examination will be emphasized to help participants build confidence in accurately diagnosing these relatively rare and often challenging to diagnose conditions. Participants will learn to develop treatment algorithms incorporating typical modalities such as sun protection, topical therapies, and antimalarials, as well as other systemic medications. The evidence for the effectiveness of these agents and their safe use in adults and children will be reviewed. Participants will be able to identify when to initiate systemic immunosuppressive therapy and/or refer to other specialists. Participants will also develop a strategy to appropriately work-up these potentially systemic conditions.
LEARNING OBJECTIVES
Utilize clinical examination to aid in accurate diagnosis of patients with cutaneous lupus erythematosus and dermatomyositis.
Develop a treatment strategy for cutaneous lupus and cutaneous dermatomyositis that incorporates modalities including sun protection, topical therapies, and systemic medications.
Describe associated systemic complications of cutaneous lupus and dermatomyositis and screen appropriately for them.
SCHEDULE
8:00 PM
Introduction
Alisa Femia, MD, FAAD
8:05 PM
Cutaneous lupus (diagnosis, evaluation, clinical features)
David A. Wetter, MD, FAAD
8:30 PM
Cutaneous lupus (treatment)
Galen Toye Foulke, MD, FAAD
9:00 PM
Q & A (Cutaneous lupus)
9:10 PM
Dermatomyositis (diagnoses, phenotypes)
Christopher T Richardson, PhD, MD, FAAD
9:35 PM
Dermatomyositis (evaluation, management)
Alisa Femia, MD, FAAD
10:00 PM
Q & A (Dermatomyositis)
10:15 PM
Challenging cases
Daniel Mazori, MD, FAAD
10:45 PM
Final Q & A
SPEAKERS
Alisa Femia, MD, FAAD
Galen Toye Foulke, MD, FAAD
Daniel Mazori, MD, FAAD
Christopher T Richardson, PhD, MD, FAAD
David A. Wetter, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Alisa Femia, MD, FAAD
No financial relationships exist with ineligible companies.
Galen Toye Foulke, MD, FAAD
American College of Physicians – Independent Contractor(Honoraria); Dermatology Foundation – Investigator(Grants/Research Funding); Gilead Sciences – Investigator(Grants/Research Funding);
Daniel Mazori, MD, FAAD
No financial relationships exist with ineligible companies.
Christopher T Richardson, PhD, MD, FAAD
AstraZeneca – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Merck – Consultant (1099 relationship)(Fees); Ribon Therapeutics – Investigator(Grants/Research Funding);
David A. Wetter, MD, FAAD
No financial relationships exist with ineligible companies.